$STXS
Stereotaxis, Inc. Stock $stxs

$stxs Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045994 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$9.196M	$4.565M
YoY Change		17.91%	-37.47%
Cost Of Revenue		$5.097M	$1.827M
YoY Change		36.28%	-38.94%
Gross Profit		$4.099M	$2.738M
YoY Change		0.99%	-36.46%
Gross Profit Margin		44.57%	59.98%
Selling, General & Admin		$7.990M	$5.830M
YoY Change		13.66%	-8.41%
% of Gross Profit		194.93%	212.93%
Research & Development		$2.454M	$2.212M
YoY Change		-8.02%	-7.83%
% of Gross Profit		59.87%	80.79%
Depreciation & Amortization		$330.0K	$135.0K
YoY Change		120.0%	3.05%
% of Gross Profit		8.05%	4.93%
Operating Expenses		$10.44M	$8.042M
YoY Change		7.69%	-8.25%
Operating Profit		-$6.345M	-$5.304M
YoY Change		12.52%	19.03%
Interest Expense		$150.0K	$261.0K
YoY Change		-44.44%	-13.58%
% of Operating Profit
Other Income/Expense, Net		$5.000K	$3.000K
YoY Change
Pretax Income		-$6.190M	-$5.040M
YoY Change		15.27%	21.33%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$6.190M	-$5.379M
YoY Change		15.29%	19.75%
Net Earnings / Revenue		-67.31%	-117.83%
Basic Earnings Per Share		-$0.08
Diluted Earnings Per Share		-$0.08	-$0.07
COMMON SHARES
Basic Shares Outstanding	84.73M shares	84.66M shares	80.88M shares
Diluted Shares Outstanding		85.82M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.66M	$19.82M
YoY Change	-51.75%	-30.29%
Cash & Equivalents	$10.66M	$19.82M
Short-Term Investments		$0.00
Other Short-Term Assets	$1.219M	$1.201M
YoY Change	-11.67%	-35.08%
Inventory	$9.009M	$8.426M
Prepaid Expenses
Receivables	$7.921M	$3.822M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$28.81M	$33.27M
YoY Change	-18.87%	-23.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.733M	$8.286M
YoY Change	8.42%	116.29%
Goodwill	$4.494M
YoY Change
Intangibles	$8.162M	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$116.0K	$356.0K
YoY Change	-76.33%	-62.61%
Total Long-Term Assets	$22.12M	$8.642M
YoY Change	145.43%	-15.0%
TOTAL ASSETS
Total Short-Term Assets	$28.81M	$33.27M
Total Long-Term Assets	$22.12M	$8.642M
Total Assets	$50.94M	$41.91M
YoY Change	14.39%	-21.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.403M	$3.190M
YoY Change	97.44%	-2.45%
Accrued Expenses	$3.376M	$3.400M
YoY Change	6.84%	2.84%
Deferred Revenue	$5.092M	$6.657M
YoY Change	-18.08%	-9.33%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.72M	$13.25M
YoY Change	59.0%	-7.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$55.00K	$6.742M
YoY Change	27.91%	13119.61%
Total Long-Term Liabilities	$55.00K	$6.742M
YoY Change	27.91%	13119.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.72M	$13.25M
Total Long-Term Liabilities	$55.00K	$6.742M
Total Liabilities	$34.71M	$19.99M
YoY Change	71.59%	-6.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$554.2M	-$537.7M
YoY Change	4.05%	4.01%
Common Stock	$85.00K	$81.00K
YoY Change	4.94%	8.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.82M	$21.92M
YoY Change
Total Liabilities & Shareholders Equity	$50.94M	$41.91M
YoY Change	14.39%	-21.54%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$6.190M	-$5.379M
YoY Change	15.29%	19.75%
Depreciation, Depletion And Amortization	$330.0K	$135.0K
YoY Change	120.0%	3.05%
Cash From Operating Activities	-$4.329M	-$2.439M
YoY Change	346.29%	-4.43%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	-$4.000K
YoY Change	0.0%	-101.08%
Acquisitions
YoY Change
Other Investing Activities	$108.0K	$1.000K
YoY Change		-100.01%
Cash From Investing Activities	$98.00K	-$5.000K
YoY Change	-1080.0%	-99.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	80.00K	21.00K
YoY Change	166.67%	-65.57%
NET CHANGE
Cash From Operating Activities	-4.329M	-2.439M
Cash From Investing Activities	98.00K	-5.000K
Cash From Financing Activities	80.00K	21.00K
Net Change In Cash	-4.151M	-2.423M
YoY Change	336.95%	-89.27%
FREE CASH FLOW
Cash From Operating Activities	-$4.329M	-$2.439M
Capital Expenditures	$10.00K	-$4.000K
Free Cash Flow	-$4.339M	-$2.435M
YoY Change	342.76%	-16.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19818000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	525000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3822000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	8426000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	676000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	33267000	usd
	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3304000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001289340
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent		usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent		usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent		usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization		usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1		usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments		usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent		usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2024Q3	STXS	Debt Securities Held To Maturity Inclusive Of Cash And Cash Equivalents At Carrying Value Gross Unrealized Gains DebtSecuritiesHeldToMaturityInclusiveOfCashAndCashEquivalentsAtCarryingValueGrossUnrealizedGains		usd
CY2024Q3	STXS	Debt Securities Held To Maturity Inclusive Of Cash And Cash Equivalents At Carrying Value Gross Unrealized Losses DebtSecuritiesHeldToMaturityInclusiveOfCashAndCashEquivalentsAtCarryingValueGrossUnrealizedLosses		usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent		usd
CY2023Q4	STXS	Debt Securities Held To Maturity Inclusive Of Cash And Cash Equivalents At Carrying Value Gross Unrealized Gains DebtSecuritiesHeldToMaturityInclusiveOfCashAndCashEquivalentsAtCarryingValueGrossUnrealizedGains		usd
CY2023Q4	STXS	Debt Securities Held To Maturity Inclusive Of Cash And Cash Equivalents At Carrying Value Gross Unrealized Losses DebtSecuritiesHeldToMaturityInclusiveOfCashAndCashEquivalentsAtCarryingValueGrossUnrealizedLosses		usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2024Q3	STXS	Accrued Licenses And Maintenance Fees Current And Noncurrent AccruedLicensesAndMaintenanceFeesCurrentAndNoncurrent		usd
CY2023Q4	STXS	Accrued Investigational Sites AccruedInvestigationalSites		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36159
	dei	Entity Registrant Name EntityRegistrantName	STEREOTAXIS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3120386
	dei	Entity Address Address Line1 EntityAddressAddressLine1	710 North Tucker Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
	dei	Entity Address City Or Town EntityAddressCityOrTown	St. Louis
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	63101
	dei	City Area Code CityAreaCode	(314)
	dei	Local Phone Number LocalPhoneNumber	678-6100
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	STXS
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	84729507	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10663000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	350000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	661000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	672000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7921000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	9009000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	869000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	28812000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3733000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	4494000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8162000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	219000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5618000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4982000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	116000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	137000	usd
CY2024Q3	us-gaap	Assets Assets	50935000	usd
CY2023Q4	us-gaap	Assets Assets	41909000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6403000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3190000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3376000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2972000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5092000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6657000	usd
CY2024Q3	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	5298000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	552000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	428000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20721000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13247000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2102000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1637000	usd
CY2024Q3	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	6251000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5583000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5062000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	43000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	34712000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	19989000	usd
CY2024Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21683	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22358	shares
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5408000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5577000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	84713400	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80949697	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	85000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	81000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	565146000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	554148000	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4015	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4015	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	206000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	206000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-554210000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-537680000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	10815000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16343000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50935000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41909000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9196000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7799000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20578000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22206000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	5097000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	3740000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	9200000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	10084000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	4099000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	4059000	usd
	us-gaap	Gross Profit GrossProfit	11378000	usd
	us-gaap	Gross Profit GrossProfit	12122000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2454000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2668000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6970000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8061000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3152000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3097000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9456000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9585000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4838000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3933000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12064000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11011000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	10444000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	9698000	usd
	us-gaap	Operating Expenses OperatingExpenses	28490000	usd
	us-gaap	Operating Expenses OperatingExpenses	28657000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6345000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5639000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17112000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16535000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	27000	usd
CY2024Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	150000	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	270000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	580000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	835000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-6190000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5369000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16530000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15673000	usd
CY2024Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	328000	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	338000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	984000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1004000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6518000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5707000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17514000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16677000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85824789	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82468971	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84629531	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	80028243	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85824789	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82468971	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84629531	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80028243	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	21386000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2672000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5369000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	25000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	18715000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	11356000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3000000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2570000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-6190000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	25000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	10815000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26346000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-18000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7987000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15673000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	73000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	18715000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16343000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16343000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	66000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3000000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7696000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16530000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	72000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	168000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	10815000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	10815000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16530000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15673000	usd
	us-gaap	Depreciation Depreciation	428000	usd
	us-gaap	Depreciation Depreciation	457000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	178000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	672000	usd
	STXS	Operating Lease Expense Income OperatingLeaseExpenseIncome	7000	usd
	STXS	Operating Lease Expense Income OperatingLeaseExpenseIncome	23000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7696000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7987000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	287000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3401000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	156000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-619000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1088000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	177000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-470000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-21000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-73000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1448000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	270000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	364000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-146000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1100000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-798000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	12000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-8000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9763000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6700000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	32000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	366000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	20131000	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	108000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	76000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19765000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	138000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	55000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	138000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9549000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13120000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20562000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9855000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11013000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22975000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10663000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22100000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	350000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	525000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	350000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11013000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	22975000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_802_eus-gaap--NatureOfOperations_zo7G8T9CoKec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. <span id="xdx_823_zYvVYuHfAT38">Description of Business</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stereotaxis designs, manufactures and markets robotic systems, instruments and information systems for the interventional laboratory. Our proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Direct control of the tip of an interventional device, in contrast to all manual hand-held devices that are controlled from their handle, can improve the precision, stability, reach and safety of these devices during procedures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary clinical focus has been electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias. Cardiac ablation has become a well-accepted therapy for arrhythmias and a multi-billion-dollar medical device market with expectations for substantial long-term growth. Our product strategy is to expand the clinical focus of our technology to several additional endovascular indications including coronary, neuro, and peripheral interventions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial real-world evidence and clinical literature for Robotic Magnetic Navigation in electrophysiology. Hundreds of electrophysiologists at over one hundred hospitals globally have treated over 150,000 arrhythmia patients with our robotic technology. Clinical use of our technology has been documented in over 500 clinical publications. Robotic Magnetic Navigation is designed to enable physicians to complete more complex interventional procedures with greater success and safety by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied computer-controlled magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation. The more flexible atraumatic design of catheters driven using magnetic fields may reduce the risk of patient harm and other adverse events. Performing the procedure from a control cockpit enables physicians to complete procedures in a safe location protected from x-ray exposure, with greater ergonomics, and improved efficiency. We believe these benefits can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure, and we are investing in research and development in these areas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary products include the <i>Genesis RMN </i>System, the <i>Odyssey </i>Solution, and other related devices. Through our strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, we offer our customers x-ray systems and other accessory devices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <i>Genesis RMN System</i> is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation, efficient procedures, and reduced x-ray exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <i>Odyssey Solution</i> consolidates lab information onto one large integrated display, enabling physicians to view and control all the key information in the operating room. This is designed to improve lab layout and procedure efficiency. The system also features a remote viewing and recording capability called <i>Odyssey Cinema,</i> which is an innovative solution that delivers synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation, and training.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have arrangements with fluoroscopy system manufacturers to provide such systems in a bundled purchase offer for hospitals establishing robotic interventional operating rooms. These are single-plane, full-power x-ray systems and include the c-arm and powered table. The combination of RMN Systems with our partnered x-ray systems reduces the cost of acquisition, the ongoing cost of ownership, and the complexity of installation of a robotic electrophysiology practice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We promote our full suite of products in a typical hospital implementation, subject to regulatory approvals or clearances. This implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond the warranty period, and ongoing software updates. In hospitals where our full suite of products has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have received regulatory clearances and approvals necessary for us to market the <i>Genesis RMN</i> System in the U.S. and Europe, and we are in the process of obtaining necessary registrations for extending our markets in other countries. The <i>Niobe</i> System, our prior generation robotic magnetic navigation system, the <i>Odyssey</i> Solution, <i>Cardiodrive</i>, e-Contact, and various disposable interventional devices have received regulatory clearances and approvals in the U.S., Europe, Canada, China, Japan and various other countries. We have regulatory clearances and approvals that allow us to market the Vdrive and Vdrive Duo Systems with the V-CAS device in the U.S., Canada and Europe. We are pursuing regulatory approvals for the Stereotaxis MAGiC catheter, a robotically-navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures, in various global geographies. Approval processes can be lengthy and uncertain, submissions may require revised or additional non-clinical and clinical data, and regulatory applications could be denied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have strategic relationships with technology leaders and innovators in the global interventional market. Through these strategic relationships we provide compatibility between our robotic magnetic navigation system, x-ray systems, and digital imaging and 3D catheter location sensing technology, as well as disposable interventional devices. The maintenance of these strategic relationships, or the establishment of equivalent alternatives, is critical to our commercialization efforts. There are no guarantees that any existing strategic relationships will continue, and efforts are ongoing to ensure the availability of compatible systems and devices and/or equivalent alternatives. We cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2024, the Company completed its acquisition of all the shares of capital stock of Access Point Technologies EP, Inc., a Minnesota corporation (“APT”), from APT Holding Company, Inc., a Minnesota corporation. APT, based in Rogers, Minnesota, designs, manufactures, and commercializes a portfolio of differentiated high-quality diagnostic catheters used during cardiac ablation procedures that are commercially available across key global geographies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The integration with APT provides in-house catheter development, manufacturing expertise and specialized knowledge that will further Stereotaxis’ innovation efforts in developing a broad family of interventional devices navigated by our robots within electrophysiology and across a range of endovascular procedures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zHB7hsCELIc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zuldm5uvvhog">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. Our investments may include, at any time, a diversified portfolio of cash equivalents and short-term and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company closely monitors events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, including Silicon Valley Bank. On March 10, 2023, Silicon Valley Bank (“SVB”), where the Company maintained accounts with a cash balance of less than 6% of the Company’s total cash, cash equivalents and marketable securities, was closed by the California Department of Financial Protection and Innovation and the FDIC was appointed as receiver. On March 12, 2023, the U.S. Department of the Treasury, Federal Reserve Board, and FDIC released a joint statement announcing that the FDIC would complete its resolution of SVB in a manner that fully protected all depositors at SVB and that depositors would have access to all of their money starting March 13, 2023. On March 26, 2023, it was announced that First-Citizens Bank & Trust Company would assume all of SVB’s deposits and loans as of March 27, 2023. During the periods presented, the Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	400000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	700000	usd
	STXS	Expected Credit Loss On Investments And Accrued Interest Description ExpectedCreditLossOnInvestmentsAndAccruedInterestDescription	The Company did not have any material expected credit losses on investments or material expected credit losses on accrued interest related to investments during the nine months ended September 30, 2024, or year ended December 31, 2023.
CY2023	STXS	Expected Credit Loss On Investments And Accrued Interest Description ExpectedCreditLossOnInvestmentsAndAccruedInterestDescription	The Company did not have any material expected credit losses on investments or material expected credit losses on accrued interest related to investments during the nine months ended September 30, 2024, or year ended December 31, 2023.
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9196000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7799000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20578000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22206000	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	15500000	usd
CY2024Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	940000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	72000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7194000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8294000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2102000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1637000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5092000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6657000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5100000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5700000	usd
CY2024Q3	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	100000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.76	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-6190000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5369000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16530000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15673000	usd
CY2024Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	328000	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	338000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	984000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1004000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6518000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5707000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17514000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16677000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85824789	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85824789	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82468971	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82468971	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84629531	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84629531	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	80028243	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80028243	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2024Q3	STXS	Business Combination Consideration Transferred Including Upfront Payment BusinessCombinationConsiderationTransferredIncludingUpfrontPayment	13877	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	19000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	672000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	672000	usd
CY2024Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	9686	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	23519	usd
CY2023Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	9349	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	27404	usd
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	235	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	368	usd
CY2024Q3	STXS	Debt Securities Held To Maturity Inclusive Of Cash And Cash Equivalents At Carrying Value Amortized Costs DebtSecuritiesHeldToMaturityInclusiveOfCashAndCashEquivalentsAtCarryingValueAmortizedCosts	11013000	usd
CY2024Q3	STXS	Debt Securities Held To Maturity Inclusive Of Cash And Cash Equivalents Fair Value Disclosure DebtSecuritiesHeldToMaturityInclusiveOfCashAndCashEquivalentsFairValueDisclosure	11013000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10663000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	350000	usd
CY2023Q4	STXS	Debt Securities Held To Maturity Inclusive Of Cash And Cash Equivalents At Carrying Value Amortized Costs DebtSecuritiesHeldToMaturityInclusiveOfCashAndCashEquivalentsAtCarryingValueAmortizedCosts	20562000	usd
CY2023Q4	STXS	Debt Securities Held To Maturity Inclusive Of Cash And Cash Equivalents Fair Value Disclosure DebtSecuritiesHeldToMaturityInclusiveOfCashAndCashEquivalentsFairValueDisclosure	20562000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19818000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	525000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	219000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	600000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1100000	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	5974000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5918000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	893000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1034000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4950000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3413000	usd
CY2024Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2808000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1939000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	9009000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	8426000	usd
CY2024Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2800000	usd
CY2024Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	332000	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	181000	usd
CY2024Q3	STXS	Prepaid Commissions Current And Noncurrent PrepaidCommissionsCurrentAndNoncurrent	83000	usd
CY2023Q4	STXS	Prepaid Commissions Current And Noncurrent PrepaidCommissionsCurrentAndNoncurrent	110000	usd
CY2024Q3	us-gaap	Deposits Assets DepositsAssets	495000	usd
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	424000	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	75000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	98000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	985000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	813000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	116000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	137000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	869000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	676000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8025000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7180000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4292000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3876000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3733000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3304000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8340000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-178000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8162000	usd
CY2024Q3	STXS	Operating Lease Right Of Use Asset And Liability OperatingLeaseRightOfUseAssetAndLiability	1000000.0	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0900	pure
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M2D
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	256000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	227000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	710000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	681000	usd
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1000	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	9000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	257000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	231000	usd
	us-gaap	Lease Cost LeaseCost	719000	usd
	us-gaap	Lease Cost LeaseCost	694000	usd
CY2024Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	286000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	255000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	797000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	741000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	265000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1079000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1097000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1122000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1147000	usd
CY2024Q3	STXS	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	3705000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8415000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2280000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	6135000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1636000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1222000	usd
CY2023Q4	STXS	Accrued Licenses And Maintenance Fees Current And Noncurrent AccruedLicensesAndMaintenanceFeesCurrentAndNoncurrent	484000	usd
CY2024Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	65000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	107000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	462000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	138000	usd
CY2024Q3	STXS	Accrued Investigational Sites AccruedInvestigationalSites	138000	usd
CY2024Q3	us-gaap	Contractual Obligation ContractualObligation	1045000	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	1045000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	85000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	19000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3431000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3015000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	43000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3376000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2972000	usd
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of common stock are entitled to one vote for each share held
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3300000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	107000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	163000	usd
	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-2000	usd
CY2023	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	547000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	40000	usd
CY2023	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	603000	usd
CY2024Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	65000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	107000	usd
CY2024Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	600000	usd
CY2024Q3	ecd	Trd Arr Adoption Date TrdArrAdoptionDate	September 1, 2024
CY2024Q3	ecd	Trd Arr Ind Name TrdArrIndName	Ms. Kimberly Peery
CY2024Q3	ecd	Trd Arr Ind Title TrdArrIndTitle	Chief Financial Officer
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2024Q3	ecd	Trd Arr Securities Agg Avail Amt TrdArrSecuritiesAggAvailAmt	165750	shares

Files In Submission

Name	View Source	Status
0001493152-24-045994-index-headers.html	Edgar Link	pending
0001493152-24-045994-index.html	Edgar Link	pending
0001493152-24-045994.txt	Edgar Link	pending
0001493152-24-045994-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stxs-20240930.xsd	Edgar Link	pending
stxs-20240930_cal.xml	Edgar Link	unprocessable
stxs-20240930_def.xml	Edgar Link	unprocessable
stxs-20240930_lab.xml	Edgar Link	unprocessable
stxs-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STXS
Stereotaxis, Inc. Stock $stxs

2024 Q4 Form 10-Q Financial Statement

#000149315224045994 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STXS Stereotaxis, Inc. Stock $stxs

2024 Q4 Form 10-Q Financial Statement

#000149315224045994 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STXS
Stereotaxis, Inc. Stock $stxs